Abstract Details

Title Improving Median Overall Survival (OS) of Glioblastoma (GBM) Patients by Optimizing Standard of Care (SOC) Through Multidisciplinary Team Work and Combination Therapies Including Tumor Treating Fields (TTF)

Topic Neuro-oncology

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-009

Objective

To evaluate if timely determination of GBM at recurrence followed by combination interventions from a multidisciplinary team may improve patients' survival who received SOC treatments (surgery, Stupp's regimen +/-TTF and bevacizumab-based chemotherapy).

Background GBM is the most common malignant primary intracranial tumor with a very poor prognosis. The median OS results are 11 months in the USA populace with SOC and 14.6 to 20.9 months in clinical trial cohorts.

Design/Methods Single-institution retrospective study of 528 eligible IDH wild-type GBM patients by WHO 2021 criteria from 2002 to 2024 was performed. Patients’ clinical information, treatments received, MRIs, adverse events, and molecular data were collected and analyzed. Survival results were calculated by the Kaplan-Meier method.

Results The extent of resection, GTR, NTR and STR, measured by post-operative MRI from the initial craniotomy were 36.1%, 17.2% and 36.3%, respectively. Among 202 patients with MGMT records, 37.13% were methylated while 62.87% were unmethylated. The Stupp regimen and Stupp regimen with TTF were administered in 81.25% and 10.79% patients, respectively. The OS for all patients is 19 months with 20, 40, 60 months OSs at 36.55%, 11.17%, 6.06%, respectively. For patients who received temozolomide/bevacizumab/irinotecan (TBI) (N = 47), TBI+TTF (N = 42), or the physician’s choice group (PCG) (N = 352), the OSs were 24, 20 and 13 months, respectively. Both TBI and TBI+TTF cohorts demonstrated statistically significant OS benefit when comparing with the PCG cohort (TBI: HR 0.51, 95% CI 0.33-0.78, p = 0.002) and (TBI+TTF: HR 0.54, 95% CI 0.33-0.90, p = 0.017). Reversible and manageable ≥ grade 3 adverse effects were observed including lymphopenia, (51.0% vs 41.2% vs 31.1%), hypertension (26.5% vs. 21.6% vs. 13.1%), and leukopenia (10.2% vs. 9.8% vs. 13.1%).

Conclusions Timely determination of GBM at recurrence followed with combination of SOC interventions by a multidisciplinary team appears to improve survival in GBM patients.

Authors/Disclosures
Jay-Jiguang Zhu, MD, PhD, FAAN (Univ of Texas Health Science Center in Houston) PRESENTER	The institution of Dr. Zhu has received research support from Novocure, Inc. The institution of Dr. Zhu has received research support from ABM Therapeutics Corporation . The institution of Dr. Zhu has received research support from Chimerix Inc.
Zhihua Chen, MD, PhD	Dr. Chen has received personal compensation for serving as an employee of UTHealth Houston.
Joshua Nahm (UTHealth Houston)	No disclosure on file
Eva H. Schumann	Ms. Schumann has received personal compensation for serving as an employee of Diakonos Oncology.
MOUSUMI SINHA, BioStatistician	Mrs. SINHA has nothing to disclose.
Mia Vu, CRC	Miss Vu has nothing to disclose.
Angel Bueno, Medical Student	Mr. Bueno has nothing to disclose.
Nitin Tandon	Nitin Tandon has stock in BrainDynamics. The institution of Nitin Tandon has received research support from NIH.
Sigmund H. Hsu, MD (New York Hospital)	No disclosure on file
Christian Amezquita Contreras (Univ of Texas Health Science Center in Houston)	Christian Amezquita Contreras has nothing to disclose.
Yoshua Esquenazi, MD	Dr. Esquenazi has nothing to disclose.

��ɫ��

��ɫ��